Xofluza® – Baloxavir marboxil is an antiviral drug with activity against influenza virus
Xofluza® is indicated for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours and who are:
- otherwise healthy, or
- at high risk of developing influenza-related
Xofluza (baloxavir marboxil) is indicated for the treatment acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours.
Limitations of Use:
Influenza viruses change over time, and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use Xofluza
Dosage Forms and Strengths
Xofluza 20 mg Tablets are white to light yellow, oblong shaped film-coated tablets debossed with “772″ on one side and “20” on the other side.
Xofluza 40 mg Tablets are white to light yellow, oblong shaped film-coated tablets debossed with “BXM40” on one side.
Xofluza is contraindicated in patients with a history of hypersensitivity to baloxavir marboxil or any of its ingredients. Serious allergic reactions have included anaphylaxis, angioedema, urticaria and erythema multiforme